TNF Inhibitor denied for missing prior authorization by OptumRx?

Adalimumab biosimilar preferred (Cyltezo / Hyrimoz / Adalimumab-adaz). Step therapy from biosimilar. Self-administered — Part D / pharmacy benefit.

OptumRx Continuity of Care provisions for >180-day stable patients. ACR 2019 anti-non-medical-switching position. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241).

## Why OptumRx Denied Your TNF Inhibitor for Prior Authorization

OptumRx requires prior authorization (PA) for TNF inhibitors before dispensing. A prior-auth-required denial means either that no PA was submitted before the prescription was filled or transmitted, or that a PA was submitted but the documentation provided did not satisfy all of the criteria in OptumRx's clinical coverage policy for this drug class. Biologics are almost universally subject to PA under commercial and Medicare Part D plans because of their cost and the existence of established step-therapy protocols.

## Why This Denial Is Appealable

If the PA was simply not submitted in advance, the practical first step is to have your prescriber submit one now with complete supporting documentation — many plans allow retroactive review under urgent or extenuating circumstances. If a PA was submitted and denied for incomplete documentation, an appeal with the missing clinical records frequently succeeds because the underlying medical need often clearly exists. If you believe the PA criteria themselves are clinically inappropriate as applied to your case, you may appeal on medical-necessity grounds as well.

## Federal Appeal Rights

A prior-auth denial is an adverse benefit determination subject to full appeal rights under ERISA §503 and ACA §2719. The plan must provide the specific criteria it applied and its complete claim file. If the internal appeal is denied, you may request independent external review — typically within 4 months of the adverse determination. Expedited internal and external review (72-hour decisions) are available when delay would seriously jeopardize your health.

## Concrete Appeal Steps and Timeline

1. Confirm with your prescriber's office whether a PA was submitted and, if so, what documentation was included. 2. Request the OptumRx clinical coverage policy for this TNF inhibitor so you know exactly what criteria must be satisfied. 3. If no PA was submitted, have your prescriber submit one immediately with complete documentation; ask whether the plan will conduct retroactive review. 4. If the PA was denied, file a Level 1 internal appeal within the deadline shown on your denial letter (typically 180 days), attaching the complete documentation package described below. 5. If the internal appeal is upheld against you, immediately request external review.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, specialist records, relevant lab or imaging results establishing the diagnosis and its current activity or severity.
• Prior-treatment history: Documentation of each treatment the policy requires to have been tried first — names, start/stop dates, and documented clinical outcomes or reasons for discontinuation.
• Clinical severity evidence: Physician assessments, validated scoring tools noted in the chart, or functional-status documentation describing how the condition affects the patient.
• Prescriber medical-necessity letter: A detailed letter from the treating physician addressing each PA criterion directly, explaining why the TNF inhibitor is medically necessary and citing the relevant professional society guideline organization.
• Absence of contraindications to required step-therapy agents: If a prior-auth criterion requires you to first try another drug but that drug is contraindicated for you, document the contraindication explicitly from the chart.

## Criteria-Mapping Structure

Obtain the exact text of OptumRx's PA criteria for this drug. In your appeal letter, reproduce each criterion verbatim, followed immediately by the chart-based evidence that satisfies it (record date and source in parentheses). This one-to-one mapping is the most effective format for a PA appeal and reduces the likelihood of a second denial due to incomplete documentation.